Literature DB >> 33440055

A proof-of-concept study of an automated solution for clinical metagenomic next-generation sequencing.

Y Luan1,2,3, H Hu1,2,3, C Liu4, B Chen4, X Liu1,2,3, Y Xu1,2,3, X Luo1,2,3, J Chen4, B Ye4, F Huang4, J Wang4, C Duan1,2,3.   

Abstract

AIMS: Metagenomic next-generation sequencing (mNGS) has been utilized for diagnosing infectious diseases. It is a culture-free and hypothesis-free nucleic acid test for diagnosing all pathogens with known genomic sequences, including bacteria, fungi, viruses and parasites. While this technique greatly expands the clinical capacity of pathogen detection, it is a second-line choice due to lengthy procedures and microbial contaminations introduced from wet-lab processes. As a result, we aimed to reduce the hands-on time and exogenous contaminations in mNGS. METHODS AND
RESULTS: We developed a device (NGSmaster) that automates the wet-lab workflow, including nucleic acid extraction, PCR-free library preparation and purification. It shortens the sample-to-results time to 16 and 18·5 h for DNA and RNA sequencing respectively. We used it to test cultured bacteria for validation of the workflow and bioinformatic pipeline. We also compared PCR-free with PCR-based library prep and discovered no differences in microbial reads. Moreover we analysed results by automation and manual testing and found that automation can significantly reduce microbial contaminations. Finally, we tested artificial and clinical samples and showed mNGS results were concordant with traditional culture.
CONCLUSION: NGSmaster can fulfil the microbiological diagnostic needs in a variety of sample types. SIGNIFICANCE AND IMPACT OF THE STUDY: This study opens up an opportunity of performing in-house mNGS to reduce turnaround time and workload, instead of transferring potentially contagious specimen to a third-party laboratory.
© 2021 The Society for Applied Microbiology.

Entities:  

Keywords:  PCR-free library preparation; automation; diagnosis of infectious diseases; metagenomic next-generation sequencing

Year:  2021        PMID: 33440055     DOI: 10.1111/jam.15003

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  5 in total

1.  Diagnosis and Surveillance of Neonatal Infections by Metagenomic Next-Generation Sequencing.

Authors:  Rong Zhang; Yan Zhuang; Zheng-Hui Xiao; Cai-Yun Li; Fan Zhang; Wei-Qing Huang; Min Zhang; Xiao-Ming Peng; Chao Liu
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640

2.  Integration of Interleukin-6 Improves the Diagnostic Precision of Metagenomic Next-Generation Sequencing for Infection in Immunocompromised Children.

Authors:  Di Wang; Min Lai; Hua Song; Jing-Ying Zhang; Fen-Ying Zhao; Juan Liang; Wei-Qun Xu; Yong-Min Tang; Xiao-Jun Xu
Journal:  Front Microbiol       Date:  2022-03-08       Impact factor: 5.640

3.  Simultaneous Detection of Pathogens and Tumors in Patients With Suspected Infections by Next-Generation Sequencing.

Authors:  Jiachun Su; Xu Han; Xiaogang Xu; Wenchao Ding; Ming Li; Weiqin Wang; Mi Tian; Xiyuan Chen; Binbin Xu; Zhongqing Chen; Jinyi Yuan; Xiaohua Qin; Dongfang Lin; Ruilan Wang; Ye Gong; Liping Pan; Jun Wang; Minggui Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-06-09       Impact factor: 6.073

4.  Severe skin and subcutaneous pythiosis in China: Metagenomic identification and characterization of Pythium insidiosum.

Authors:  Haiyan Zhang; Fengli Zhou; Jiabao Huang; Xiaoyun Liu; Hui Xu; Jiayin Liang; Jun Wang; Jing Chen; Lingling Liu; Yiting Li; Xuan Hu; Xuanrong Chen; Chao Liu; Kouxing Zhang
Journal:  Front Microbiol       Date:  2022-09-30       Impact factor: 6.064

5.  The diagnosis of leptospirosis complicated by pulmonary tuberculosis complemented by metagenomic next-generation sequencing: A case report.

Authors:  Jichan Shi; Wenjie Wu; Kang Wu; Chaorong Ni; Guiqing He; Shilin Zheng; Fang Cheng; Yaxing Yi; Ruotong Ren; Xiangao Jiang
Journal:  Front Cell Infect Microbiol       Date:  2022-10-04       Impact factor: 6.073

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.